Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.

Saved in:
Bibliographic Details
Title: Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.
Authors: Garcia-Rendueles AR; Centre for Investigations in Molecular Medicine and Chronic Disease (CIMUS) and Institute of Investigaciones Sanitarias (IDIS), Group of Endocrine Neoplasia and Differentiation, University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Rodrigues JS; Centre for Investigations in Molecular Medicine and Chronic Disease (CIMUS) and Institute of Investigaciones Sanitarias (IDIS), Group of Endocrine Neoplasia and Differentiation, University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Garcia-Rendueles ME; Centre for Investigations in Molecular Medicine and Chronic Disease (CIMUS) and Institute of Investigaciones Sanitarias (IDIS), Group of Endocrine Neoplasia and Differentiation, University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Suarez-Fariña M; Centre for Investigations in Molecular Medicine and Chronic Disease (CIMUS) and Institute of Investigaciones Sanitarias (IDIS), Group of Endocrine Neoplasia and Differentiation, University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Perez-Romero S; Centre for Investigations in Molecular Medicine and Chronic Disease (CIMUS) and Institute of Investigaciones Sanitarias (IDIS), Group of Endocrine Neoplasia and Differentiation, University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Barreiro F; Department of Surgery, University Hospital of Santiago de Compostela (CHUS) & University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Bernabeu I; Department of Endocrinology, University Hospital of Santiago de Compostela (CHUS) & University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Rodriguez-Garcia J; Department of Clinical Biochemistry, University Hospital of Santiago de Compostela (CHUS) & University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Fugazzola L; Endocrine Unit, Fondazione IRCCS Ca' Granda Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy., Sakai T; Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan., Liu F; Center for Advanced Biotechnology and Medicine, Susan Lehman Cullman Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, Piscataway, NJ, USA., Cameselle-Teijeiro J; Department of Pathology, University Hospital of Santiago de Compostela (CHUS) & University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Bravo SB; Department of Proteomics, University Hospital of Santiago de Compostela (CHUS), Santiago de Compostela, Spain., Alvarez CV; Centre for Investigations in Molecular Medicine and Chronic Disease (CIMUS) and Institute of Investigaciones Sanitarias (IDIS), Group of Endocrine Neoplasia and Differentiation, University of Santiago de Compostela (USC), Santiago de Compostela, Spain.
Source: Oncogene [Oncogene] 2017 Feb 02; Vol. 36 (5), pp. 652-666. Date of Electronic Publication: 2016 Jul 25.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5594
DOI:10.1038/onc.2016.233